Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24756635 | 0.90 | MEN1 (0.51) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL15229234 | 0.90 | L3MBTL4 (0.53) | MEN1KMT2APOLBHDAC4SMN1; SMN2 | |
| SCHEMBL34473168 | 0.88 | MEN1 (0.57) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL1088556 | 0.86 | TDP1 (0.61) | MEN1KMT2APOLBGPR119TDP1 | |
| SCHEMBL3960220 | 0.83 | MEN1 (0.66) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL15229029 | 0.83 | HDAC4 (0.49) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL13872069 | 0.81 | KMT2A (0.60) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL17714087 | 0.79 | MEN1 (0.54) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL29230243 | 0.79 | MEN1 (0.54) | MEN1KMT2APOLBHDAC4GPR119 | |
| SCHEMBL29632731 | 0.79 | MEN1 (0.54) | MEN1KMT2APOLBHDAC4CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | MEN1 880/4885KMT2A 2796/4885POLB 783/4885 |
| US-20090111795-A1 | Multimers of Heterocyclic Compounds and Their Use | MRM1, ME2, SDHA | MEN1 189/4885KMT2A 1650/4885POLB 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.